AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|
17.3 C
New York
Friday, October 16, 2026

Tag: arm

PURECORE COMPLETES PHASE ONE EXPLORATION AT CRITICAL MINERALS PROJECT, BANKIER

VANCOUVER, BC, July 22, 2026 /CNW/ -- Purecore Metals Inc. (CSE: PURE) (FSE: J8Y) ("Purecore" or the "Company") is pleased to announce geologists from HEG &...

INTURAI ADVANCES DRONE, DEFENCE AND IN-HOME INTELLIGENCE WITH NEW TECHNOLOGY

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)investor@inturai.comHighlightsInturai's sensors now work without an internet connection, making them much easier to set up and more...

INTURAI ADVANCES DRONE, DEFENCE AND IN-HOME INTELLIGENCE WITH NEW TECHNOLOGY

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)investor@inturai.comHighlightsInturai's sensors now work without an internet connection, making them much easier to set up and more...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

SOMA GOLD CLOSES $7.5 MILLION LIFE OFFERING

VANCOUVER, BC, June 25, 2026 /CNW/ - Soma Gold Corp. (TSXV: SOMA) (WKN: A2P4DU) (OTC: SMAGF) (the "Company" or "Soma") is pleased to announce...

Orbital Composites Wins U.S. Space Force Contract to Advance Extreme Environment Materials Manufacturing

SpaceWERX TACFI award advances Orbital's path toward AI-driven factories for extreme environment materials — targeting the critical U.S. capacity gap in components that underpin...

A Drilling Crew, an Icebreaker, and a Path to an Open Pit at Skaergaard

Issued on behalf of Greenland Mines Ltd.Greenland Mines Ltd. (Nasdaq: GRML) has signed a diamond drilling contract with Arctic specialist Nordisk Fundering for a...

EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

Taipei AI Companies Head to NextRise 2026, Strengthening Asia’s Hub for Enterprise AI Collaboration

TAIPEI, June 25, 2026 /PRNewswire/ -- Led by the Department of Economic Development, Taipei City Government, the StartUP@Taipei program brought 10 Taipei-based AI companies...

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsArm